C4 Therapeutics Stock Performance
| CCCC Stock | USD 4.38 0.13 3.06% |
The firm owns a Beta (Systematic Risk) of 1.34, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, C4 Therapeutics will likely underperform. At this point, C4 Therapeutics has a negative expected return of -0.48%. Please make sure to confirm C4 Therapeutics' total risk alpha, potential upside, and the relationship between the standard deviation and maximum drawdown , to decide if C4 Therapeutics performance from the past will be repeated sooner or later.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days C4 Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of conflicting performance in the last few months, the Stock's fundamental indicators remain rather sound which may send shares a bit higher in December 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return (1.83) | Five Day Return 6.7 | Year To Date Return (34.05) | Ten Year Return (83.13) | All Time Return (83.13) |
1 | Disposition of 2250 shares by Siegel Jolie of C4 Therapeutics subject to Rule 16b-3 | 09/16/2024 |
2 | Disposition of 661 shares by Boyle Scott N of C4 Therapeutics at 6.36 subject to Rule 16b-3 | 09/17/2024 |
3 | Disposition of 1837 shares by Kendra Adams of C4 Therapeutics at 6.38 subject to Rule 16b-3 | 09/18/2024 |
4 | BMO maintains Outperform rating on C4 Therapeutics shares - Investing.com | 09/19/2024 |
5 | Acquisition by Anderson Kenneth Carl of 2023 shares of C4 Therapeutics at 5.56 subject to Rule 16b-3 | 10/01/2024 |
6 | Crypto Content Creator Campus Unveils Star-Studded Speaker Lineup for Inaugural Event | 10/11/2024 |
7 | Insider Trading | 10/21/2024 |
8 | Acquisition by Mahaney Paige of 345600 shares of C4 Therapeutics at 6.0 subject to Rule 16b-3 | 10/29/2024 |
9 | C4 Therapeutics Q3 2024 Earnings Revenue Surges to 15.4M, GAAP EPS Loss Narrows to 0.35 | 10/31/2024 |
10 | C4 Therapeutics to Present Data from the Ongoing Phase 12 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkins Lymphoma at the American Society of Hematolo... | 11/05/2024 |
11 | C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial | 11/06/2024 |
12 | Disposition of 12500 shares by Andrew Hirsch of C4 Therapeutics subject to Rule 16b-3 | 11/07/2024 |
13 | Orbimed Advisors LLC Increases Stake in C4 Therapeutics Inc | 11/15/2024 |
14 | Stephens Initiates Coverage on C4 Therapeutics - MarketBeat | 11/18/2024 |
| Begin Period Cash Flow | 33 M |
CCCC |
C4 Therapeutics Relative Risk vs. Return Landscape
If you would invest 637.00 in C4 Therapeutics on August 28, 2024 and sell it today you would lose (199.00) from holding C4 Therapeutics or give up 31.24% of portfolio value over 90 days. C4 Therapeutics is currently does not generate positive expected returns and assumes 4.9471% risk (volatility on return distribution) over the 90 days horizon. In different words, 44% of stocks are less volatile than CCCC, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
C4 Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for C4 Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as C4 Therapeutics, and traders can use it to determine the average amount a C4 Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.096
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CCCC |
Estimated Market Risk
| 4.95 actual daily | 44 56% of assets are more volatile |
Expected Return
| -0.48 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average C4 Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of C4 Therapeutics by adding C4 Therapeutics to a well-diversified portfolio.
C4 Therapeutics Fundamentals Growth
CCCC Stock prices reflect investors' perceptions of the future prospects and financial health of C4 Therapeutics, and C4 Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CCCC Stock performance.
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (1.84) % | ||||
| Current Valuation | 111.46 M | ||||
| Shares Outstanding | 70.59 M | ||||
| Price To Book | 1.24 X | ||||
| Price To Sales | 9.18 X | ||||
| Revenue | 20.76 M | ||||
| Gross Profit | (86.75 M) | ||||
| EBITDA | (122.1 M) | ||||
| Net Income | (132.49 M) | ||||
| Cash And Equivalents | 307.78 M | ||||
| Cash Per Share | 6.29 X | ||||
| Total Debt | 70.98 M | ||||
| Debt To Equity | 0.25 % | ||||
| Current Ratio | 6.90 X | ||||
| Book Value Per Share | 3.44 X | ||||
| Cash Flow From Operations | (106.84 M) | ||||
| Earnings Per Share | (1.71) X | ||||
| Market Capitalization | 309.18 M | ||||
| Total Asset | 376.45 M | ||||
| Retained Earnings | (528.38 M) | ||||
| Working Capital | 228.42 M | ||||
| Current Asset | 1 K | ||||
| Current Liabilities | 49 K | ||||
About C4 Therapeutics Performance
By analyzing C4 Therapeutics' fundamental ratios, stakeholders can gain valuable insights into C4 Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if C4 Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if C4 Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -3.4 K | -3.2 K | |
| Return On Tangible Assets | (0.35) | (0.37) | |
| Return On Capital Employed | (0.42) | (0.44) | |
| Return On Assets | (0.35) | (0.37) | |
| Return On Equity | (0.54) | (0.51) |
Things to note about C4 Therapeutics performance evaluation
Checking the ongoing alerts about C4 Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for C4 Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| C4 Therapeutics generated a negative expected return over the last 90 days | |
| C4 Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 20.76 M. Net Loss for the year was (132.49 M) with loss before overhead, payroll, taxes, and interest of (86.75 M). | |
| C4 Therapeutics currently holds about 307.78 M in cash with (106.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 92.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Insider Trading |
- Analyzing C4 Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether C4 Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining C4 Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating C4 Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of C4 Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of C4 Therapeutics' stock. These opinions can provide insight into C4 Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CCCC Stock analysis
When running C4 Therapeutics' price analysis, check to measure C4 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy C4 Therapeutics is operating at the current time. Most of C4 Therapeutics' value examination focuses on studying past and present price action to predict the probability of C4 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move C4 Therapeutics' price. Additionally, you may evaluate how the addition of C4 Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |